Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

← catalyst calendar

NCT06420297

Sponsored by ACADIA Pharmaceuticals Inc. (industry) · ACAD — their whole pipeline →.

Phase
Phase 3
Status
Terminated
Study type
Interventional
Design
Na · None · Treatment
Enrollment
168actual
Sites
30
Countries
Canada, France, Germany +3

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Why the sponsor stopped it

Primary efficacy endpoint was not met in the parent study (ACP-101-302). Based on review of available data, continued administration of investigational product in ACP-101-303 was not considered likely to provide significant clinical benefit.

As filed on the registry record, in the sponsor's own words.

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2024-03-11actualWhen the study began enrolling
Primary completion2025-12-19actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2025-12-19actualThe whole study's end, after follow-up
First posted2024-05-20actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-08-17actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Hyperphagia in Prader-Willi Syndrome

Intervention

  • Drug: Carbetocin — also filed as ACP-101

Primary outcome

what the primary-completion date above is the date OF
Treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), withdrawals due to adverse events (AEs), potentially clinically important changes in other safety assessments, device incidents or device malfunctions
measured Baseline to 36 months

Permalink · ACAD's whole pipeline · Catalyst calendar · Every registered study · What changed